Loading organizations...
Maple Rock Capital is a global investment firm managing a concentrated portfolio of public equities. It specializes in identifying mispriced opportunities within small- and mid-cap companies, particularly those in structurally inefficient sectors. The firm employs a deep fundamental research approach to uncover value, aiming for long-term capital appreciation through active ownership.
Founded in 2014 by Xavier Majic and Lennard Kipp, Maple Rock Capital was built upon Majic's previous experience as a Managing Director at Lonestar Capital. Their founding insight focused on the belief that diligent research and active engagement with companies could unlock significant value in overlooked market segments, particularly among smaller publicly traded entities.
The firm serves institutional and high-net-worth investors seeking specialized public equity exposure. Maple Rock Capital's long-term vision is to generate superior returns by acting as a responsible, engaged owner, influencing positive change within its portfolio companies. The company is committed to fostering diversity, equity, and inclusion, and holds B Corp certification.
Maple Investment has 1 tracked investment across 1 company. The latest tracked deal is $16.0M Series B in PharmCADD in April 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 19, 2021 | PharmCADD | $16.0M Series B | Huons, Samyang Holdings, SD BIOSENSOR | Daily Partners, DSC Investment, Future Play, KB Securities, KTB Network |